Chimerism testing identifies whether cells in a person’s body come from one individual or two. The most common method uses a blood or bone marrow sample analyzed by a DNA technique called short tandem repeat (STR) analysis, which can detect a second person’s DNA when it makes up at least 1% to 5% of the total. The context matters: chimerism testing after a stem cell transplant follows a structured clinical protocol, while detecting natural chimerism (like fetal cells in a mother’s blood) or forensic chimerism requires different approaches and more sensitive tools.
Why Chimerism Testing Is Done
The vast majority of chimerism tests are performed after an allogeneic stem cell or bone marrow transplant. The goal is straightforward: confirm that the donor’s cells have engrafted and are producing the recipient’s new blood and immune system. A successful transplant means the recipient’s blood cells carry the donor’s DNA. If the recipient’s own DNA starts reappearing or increasing in those cells, it can signal graft failure or disease relapse.
Outside of transplant medicine, chimerism occasionally surfaces in forensic investigations, paternity disputes, or research into microchimerism, where tiny amounts of fetal DNA persist in a mother’s body for years or even decades after pregnancy. One landmark study found male fetal cells circulating in maternal blood as long as 27 years after delivery.
STR Analysis: The Standard Method
Short tandem repeat analysis is the workhorse of clinical chimerism testing and the current standard of care. STRs are short, repeating segments of DNA that vary predictably between individuals. Before a transplant, both the donor and recipient provide DNA samples (usually from blood or a cheek swab). The lab identifies STR markers that differ between the two people. After transplant, those same markers are tracked in the recipient’s blood or marrow to calculate what percentage of cells belong to the donor versus the recipient.
STR analysis is rapid, reliable, and reproducible, but its sensitivity has a ceiling. It reliably detects a second person’s DNA only when it represents roughly 1% to 5% of the sample. Below that threshold, STR struggles to accurately quantify small amounts of recipient DNA, which means very early signs of relapse can be missed.
Higher-Sensitivity Alternatives
When detecting tiny fractions of DNA matters, labs turn to more sensitive techniques. Quantitative PCR (qPCR) amplifies specific DNA targets and can detect chimerism below 1%. Many transplant centers historically paired STR with qPCR to get both broad accuracy and deeper sensitivity in a single workflow.
Digital PCR pushes the boundary even further. A validated droplet digital PCR method can accurately quantify chimerism down to 0.01% foreign cells, roughly 100 to 500 times more sensitive than standard STR. This level of precision is especially useful for tracking minimal residual disease, where catching even a trace increase in recipient DNA could prompt earlier intervention.
Next-generation sequencing (NGS) is a newer option that analyzes multiple insertion/deletion markers simultaneously. In clinical validation studies, NGS-based chimerism results correlated almost perfectly with combined STR/qPCR results, with no significant bias between the two approaches and 100% agreement in detecting recipient DNA increases as small as 0.1%. NGS also simplifies the lab workflow by replacing the need for two separate tests, processing 10 to 20 samples per batch with only about two hours of hands-on labor.
What Samples Are Collected
Most chimerism monitoring uses peripheral blood, drawn from a vein like any standard blood test. Bone marrow aspirate, collected through a needle inserted into the hip bone, is the other option. Both have trade-offs.
A large comparison study of 825 matched sample pairs found a statistically significant correlation between peripheral blood and bone marrow results, but bone marrow consistently detected mixed chimerism more readily. Donor chimerism measured in bone marrow tended to run about 1.9 percentage points lower than in peripheral blood. This matters because showing “complete” donor chimerism in peripheral blood turned out to be a poor predictor of complete chimerism in bone marrow, with a sensitivity of only 47.8%. In practical terms, nearly one in five tests showing full donor chimerism in blood had incomplete chimerism in marrow.
On the other hand, if peripheral blood shows incomplete donor chimerism, that finding is highly specific (97.5%) for incomplete chimerism in bone marrow as well. So a concerning result in blood is trustworthy, but an “all clear” result in blood alone can miss problems detectable in marrow. Many centers use peripheral blood for routine monitoring and reserve bone marrow sampling for key decision points.
Cell-Specific Chimerism Testing
Whole blood chimerism gives an overall picture, but it can mask important changes happening in specific cell types. To get a more detailed view, labs separate the blood sample into individual cell lineages before running STR analysis. The most clinically relevant fractions are T-cells (using the CD3 marker), myeloid cells (CD33/66b), B-cells (CD19/20), and natural killer cells (CD56).
This lineage-specific approach matters because different cell types can tell different stories. Dropping donor chimerism in the T-cell fraction may signal an increased risk of graft rejection, while falling chimerism in the myeloid fraction can be an early warning of disease relapse in blood cancers. Research in pediatric transplant recipients confirmed that whole blood chimerism alone is not sufficient to assess post-transplant status, and that lineage-specific analysis provides a more accurate picture of the dynamic engraftment process.
When and How Often Testing Happens
After a stem cell transplant, chimerism testing follows a structured schedule. UK consensus guidelines published in 2025 recommend whole blood chimerism at day 30 as a baseline check on engraftment. For patients transplanted for blood cancers, testing then expands to include both whole blood and lineage-specific chimerism (T-cell and myeloid fractions) at day 60, day 100, and every three months out to two years.
The timing of the first test carries real prognostic weight. A study of patients who received reduced-intensity transplants found that every 1% increase in whole blood donor chimerism at day 30 corresponded to a 10% decrease in relapse risk. Low donor chimerism at that early checkpoint, whether measured in whole blood or the T-cell fraction, independently predicted higher relapse rates regardless of other clinical factors.
What the Results Mean
Chimerism results are reported as a percentage of donor versus recipient DNA. Full donor chimerism is typically defined as a donor cell fraction of 95% or higher. Anything below 95% is classified as mixed chimerism, meaning a detectable portion of the recipient’s original cells remain or have returned.
Mixed chimerism is not automatically a crisis. Some degree of mixed chimerism is common in the early weeks after transplant, and stable low-level mixed chimerism can persist without clinical consequences in certain situations. The concern arises when donor chimerism is falling over time, particularly in the cell lineage related to the original disease. A trend of declining donor percentages, rather than a single snapshot, is what typically triggers clinical decisions like adjusting immunosuppression or pursuing donor lymphocyte infusions.
Chimerism in Forensic and Natural Contexts
Chimerism occasionally appears unexpectedly during forensic DNA profiling or paternity testing. A chimeric individual carrying two genetically distinct cell populations can produce confusing STR profiles, sometimes showing extra peaks at multiple markers. Sex-typing procedures using a single marker like amelogenin can give ambiguous results when someone carries both male and female cell lineages. Forensic guidelines recommend using multiplex STR analysis rather than single-marker tests, and following up suspicious samples with Y-chromosome STR typing or other highly discriminating methods.
For naturally occurring microchimerism, such as fetal cells persisting in maternal circulation, detection requires the most sensitive available techniques. The cell populations involved are vanishingly small, often far below the 1% floor of standard STR. Quantitative analysis of cell-free fetal DNA in maternal plasma, digital PCR, and targeted approaches looking for male-specific markers in mothers who carried sons are all used in research settings. These methods remain largely investigative rather than part of routine clinical care.